Skip to content

Krzysztof Brzozka

  • PhD, MBA
  • CSO, EVP
  • Selvita SA
  • 8h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 2363CitationsNumber of citations received by Krzysztof's publications. Updated daily.

Other IDs

Co-authors (94)

  • Karl-Klaus Conzelmann
  • Tomasz Rzymski

Publications (5)

  • Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma

    • Szydłowski M
    • Prochorec-Sobieszek M
    • Szumera-Ciećkiewicz A
    • et al.
    N/AReaders
    1Citations
    Get full text
  • Mitogen-activated Protein Kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) as targets for cancer therapy: Recent progress in the development of MNK inhibitors

    • Dreas A
    • Mikulski M
    • Milik M
    • et al.
    N/AReaders
    2Citations
    Get full text
  • MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma

    • Zhan Y
    • Guo J
    • Yang W
    • et al.
    N/AReaders
    0Citations
    Get full text
  • SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains

    • Rzymski T
    • Mikula M
    • Zylkiewicz E
    • et al.
    N/AReaders
    4Citations
    Get full text
  • CDK8 kinase - An emerging target in targeted cancer therapy

    • Rzymski T
    • Mikula M
    • Wiklik K
    • et al.
    N/AReaders
    14Citations
    Get full text

Professional experience

CSO, EVP

Selvita SA

January 2007 - Present